It is more important than ever to connect and share ideas. The Law Over Lunch series offers FDLI members the exclusive opportunity to engage in facilitated virtual discussions over lunch on topics of interest to the food and drug law community. This event features unique and co-occurring discussion groups, limited to ten attendees to encourage fruitful conversation. This member-only benefit is a chance to closely learn from, educate, and network with other professionals in the field on new and pertinent topics.
Please only sign up for one discussion as they will take place at the same time.
Table Topics and Facilitators
SaMD: What’s next after FDA’s Final CDS Guidance and Completion of the Pre-Cert Program?
Bethany J. Hill, Partner
DLA Piper LLP
Making Sense of Pres. Biden’s Cannabis Reform Statement – FDA’s Role in Scheduling Evaluation
Jonathan A. Havens, Partner
Saul Ewing Arnstein & Lehr LLP
Roundtable On The Current State of Class Action Litigation for Food and Dietary Supplements
Christopher Van Gundy, Partner
Sheppard Mullin Richter & Hampton LLP
BETHANY HILLS is Vice Chair of DLA Piper’s FDA practice where she advises life sciences and health tech industry clients on complex pre- and post-market product and distribution issues. Her clients span the full range of FDA regulated companies, including medical device and digital health, drug, combination product, diagnostic and biologic, as well as regenerative medicine, cosmetic, dietary supplement and food industry businesses. She also represents investor groups that focus on innovation in these industries. Bethany helps companies manage strategic and critical FDA regulation issues including product development and classification, governmental inspections and investigations, and complex regulatory challenges such as product approvals and labeling and collaborative research, supply and distribution agreements. In addition, Bethany has deep expertise in healthcare delivery systems, referral relationships, clinical trial compliance, licensure and security and privacy issues, as well as the intricacies of government and third-party reimbursement. Bethany’s practical guidance helps clients invest and collaborate strategically by identifying technologies that are likely to thrive within the healthcare delivery system, clear FDA regulatory hurdles and realize long term commercial success.
JONATHAN A. HAVENS is a partner at Saul Ewing Arnstein & Lehr LLP, where he serves as co-chair of both the firm’s Cannabis Law and Food, Beverage & Agribusiness Practices. Companies in the cannabis (both hemp and marijuana), life sciences, food and beverage, and cosmetics industries turn to Jonathan for advice on how to get and keep their products on the market. Since 2019, Chambers USA has recognized Jonathan as one of America’s leading lawyers in cannabis law. In 2021, Law360 selected Jonathan as a cannabis law rising star, making him one of only five attorneys nationwide to receive that honor. He is regularly interviewed by mainstream and trade press outlets, alike, and has been quoted by or authored pieces for The New York Times, The Los Angeles Times, Reuters, CNBC, WIRED, MarketWatch, Engadget, Law360, High Times Magazine, and Marijuana Business Daily, among others. Jonathan began his legal career as a regulatory counsel with the US Food and Drug Administration, and prior to law school, Jonathan served as a legislative aide in both the US Senate and US House of Representatives.
CHRISTOPHER VAN GUNDY is a partner at Sheppard Mullin Richter & Hampton LLP. His practice involves counseling and representing food and consumer product manufacturers, distributors, and retailers both in litigation and as to regulatory matters. He defends companies in consumer false advertising purported class actions, and advises on FDA, USDA, California Proposition 65, and CBD matters.October 27, 2022
12:00-1:00 PM ET
Registration is open to FDLI members only and is first come, first served.
This is a complimentary virtual event.
Please only sign up for one discussion as they will take place at the same time.
For questions, please contact Tess Garraty.
